Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) has reported its latest quarterly financial results against a backdrop of war in its home region.
Revenue for the third quarter of 2023 rose 7% to $3.9 billion, above the $3.72 billion predicted by analysts, I/B/E/S data from Refinitiv Eikon showed.
The increased revenues reflect sustained growth in sales of the Huntingdon’s disease drug Austedo (deutetrabenazine), the migraine product Ajovy (fremanezumab) and the global generics business.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze